Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

About Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MNTA
  • CUSIP: 60877T10
  • Web: www.momentapharma.com
Capitalization:
  • Market Cap: $1.04248 billion
  • Outstanding Shares: 76,231,000
Average Prices:
  • 50 Day Moving Avg: $15.97
  • 200 Day Moving Avg: $15.79
  • 52 Week Range: $10.75 - $19.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.01
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $113.52 million
  • Price / Sales: 9.43
  • Book Value: $5.22 per share
  • Price / Book: 2.69
Profitability:
  • EBITDA: ($83,150,000.00)
  • Net Margins: -39.35%
  • Return on Equity: -12.28%
  • Return on Assets: -9.18%
Debt:
  • Current Ratio: 4.08%
  • Quick Ratio: 4.08%
Misc:
  • Average Volume: 786,732 shs.
  • Beta: 1.83
  • Short Ratio: 9.13
 

Frequently Asked Questions for Momenta Pharmaceuticals (NASDAQ:MNTA)

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). The business earned $23.57 million during the quarter, compared to the consensus estimate of $24.64 million. Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The company's quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.31) EPS. View Momenta Pharmaceuticals' Earnings History.

When will Momenta Pharmaceuticals make its next earnings announcement?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Momenta Pharmaceuticals.

Where is Momenta Pharmaceuticals' stock going? Where will Momenta Pharmaceuticals' stock price be in 2017?

9 equities research analysts have issued 1 year target prices for Momenta Pharmaceuticals' stock. Their predictions range from $6.00 to $18.00. On average, they anticipate Momenta Pharmaceuticals' share price to reach $14.44 in the next twelve months. View Analyst Ratings for Momenta Pharmaceuticals.

What are analysts saying about Momenta Pharmaceuticals stock?

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Momenta’s sales of Glatopa 20mg continue to do well and have captured approximately 40% of the market in the U.S. We are pleased with the company’s efforts to develop biosimilars given the potential in the market with recent approvals. In addition, a potential approval of M923 will boost investor confidence. The company has collaborated with Mylan to develop, manufacture and commercialize six of its current biosimilar candidates. However, the ANDA approval for Glatopa 40mg is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Moreover, shares of the company have underperformed the industry in the last six months. The recent FDA approval of Mylan's generic version of Copaxone 40mg led to significant plunge in the share price." (10/11/2017)
  • 2. Cowen and Company analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)
  • 3. Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
  • 4. Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)

Who are some of Momenta Pharmaceuticals' key competitors?

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the folowing people:

  • Craig A. Wheeler, President, Chief Executive Officer, Director
  • Scott M. Storer, Chief Financial Officer, Senior Vice President
  • Ganesh Venkataraman Kaundinya Ph.D., Chief Operating Officer, Chief Scientific Officer
  • Bruce A. Leicher, Senior Vice President, General Counsel, Secretary
  • Bruce L. Downey, Independent Director
  • Corey N. Fishman, Independent Director
  • Georges Gemayel Ph.D., Independent Director
  • Steven C. Gilman Ph.D., Independent Director
  • Jose-Carlos Gutierrez-Ramos Ph.D., Independent Director

Who owns Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.13%) and Eqis Capital Management Inc. (0.03%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Who bought Momenta Pharmaceuticals stock? Who is buying Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Eqis Capital Management Inc.. View Insider Buying and Selling for Momenta Pharmaceuticals.

How do I buy Momenta Pharmaceuticals stock?

Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $14.05.


MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  261 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  486
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Momenta Pharmaceuticals (NASDAQ:MNTA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings
Consensus Rating:Hold (Score: 1.89)
Consensus Price Target: $14.44 (2.81% upside)
Consensus Price Target History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Price Target History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Analysts' Ratings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Robert W. BairdDowngradeBuy -> Hold$22.00 -> $15.00N/AView Rating Details
10/5/2017J P Morgan Chase & CoReiterated RatingHold$14.00N/AView Rating Details
10/5/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$18.00 -> $14.00N/AView Rating Details
10/4/2017Barclays PLCReiterated RatingEqual Weight$17.00 -> $16.00HighView Rating Details
10/4/2017Stifel NicolausReiterated RatingBuy -> Hold$22.00 -> $15.00HighView Rating Details
8/3/2017Maxim GroupSet Price TargetSell$6.00LowView Rating Details
5/3/2017Cowen and CompanyReiterated RatingHold$15.00LowView Rating Details
5/3/2017AegisReiterated RatingHold$17.00LowView Rating Details
2/21/2017Leerink SwannDowngradeOutperform -> Market Perform$18.00 -> $18.00N/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$19.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Earnings by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Earnings History by Quarter for Momenta Pharmaceuticals (NASDAQ MNTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.47)N/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.50)$24.64 million$23.57 millionViewListenView Earnings Details
5/2/2017Q1 2017($1.09)($0.46)$21.29 million$26.61 millionViewListenView Earnings Details
2/21/2017Q416($0.24)$0.60$29.56 million$34.20 millionViewListenView Earnings Details
11/2/2016Q316($0.29)($0.26)$25.68 million$299.14 millionViewN/AView Earnings Details
8/4/2016Q216($0.34)($0.31)$23.55 million$26.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.35)$28.12 million$19.90 millionViewN/AView Earnings Details
2/18/2016Q415($0.04)($0.43)$30.42 million$22.40 millionViewListenView Earnings Details
11/4/2015Q315($0.19)($0.44)$31.76 million$13.80 millionViewListenView Earnings Details
8/4/2015Q215($0.39)($0.04)$23.59 million$44.90 millionViewListenView Earnings Details
5/1/2015Q115($0.48)($0.40)$11.70 million$8.60 millionViewN/AView Earnings Details
2/17/2015Q414($0.16)($0.31)$23.80 million$21.18 millionViewListenView Earnings Details
11/5/2014Q314($0.43)($0.56)$13.00 million$9.34 millionViewListenView Earnings Details
7/31/2014Q214($0.49)($0.51)$11.22 million$11.00 millionViewListenView Earnings Details
5/6/2014Q1($0.55)($0.53)$8.41 million$10.79 millionViewListenView Earnings Details
2/10/2014Q4($0.45)($0.59)$8.50 million$12.80 millionViewListenView Earnings Details
11/5/2013Q313($0.48)($0.50)$8.60 million$10.80 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.45)($0.57)$8.85 million$4.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.44)($0.48)$10.28 million$7.60 millionViewN/AView Earnings Details
2/15/2013Q4 2012($0.41)($0.35)$10.41 million$12.70 millionViewN/AView Earnings Details
11/7/2012Q312($0.27)($0.51)$16.48 million$5.10 millionViewN/AView Earnings Details
8/2/2012($0.17)($0.20)ViewN/AView Earnings Details
5/3/2012$0.02($0.10)ViewN/AView Earnings Details
2/9/2012$0.13($0.02)ViewN/AView Earnings Details
11/7/2011$1.28$1.18ViewN/AView Earnings Details
8/4/2011$1.21$1.26ViewN/AView Earnings Details
5/5/2011$0.95$1.13ViewN/AView Earnings Details
2/10/2011$0.81$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)
2017 EPS Consensus Estimate: ($0.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.36)($0.36)($0.36)
Q2 20171($0.30)($0.30)($0.30)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171$0.28$0.28$0.28
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 93.88%
Insider Trades by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Insider Trades by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Craig A WheelerPresidentSell35,667$19.03$678,743.01View SEC Filing  
9/1/2017Craig A. WheelerPresidentSell20,367$17.00$346,239.00View SEC Filing  
8/21/2017Bruce LeicherSVPSell802$15.20$12,190.40View SEC Filing  
8/21/2017Craig A WheelerPresidentSell4,116$15.07$62,028.12View SEC Filing  
8/21/2017Ganesh Venkataraman KaundinyaVPSell821$15.20$12,479.20View SEC Filing  
8/10/2017Bruce LeicherSVPSell350$16.60$5,810.00View SEC Filing  
8/10/2017Craig A. WheelerPresidentSell16,953$16.94$287,183.82View SEC Filing  
8/10/2017Ganesh Venkataraman KaundinyaVPSell387$16.60$6,424.20View SEC Filing  
8/2/2017Craig A WheelerPresidentSell200$17.00$3,400.00View SEC Filing  
5/22/2017Bruce LeicherSVPSell859$14.80$12,713.20View SEC Filing  
5/19/2017Craig A WheelerPresidentSell4,116$15.83$65,156.28View SEC Filing  
5/19/2017Ganesh Venkataraman KaundinyaVPSell821$15.90$13,053.90View SEC Filing  
5/10/2017Bruce LeicherSVPSell347$16.00$5,552.00View SEC Filing  
5/10/2017Craig A. WheelerPresidentSell1,852$15.77$29,206.04View SEC Filing  
5/10/2017Ganesh Venkataraman KaundinyaVPSell384$16.00$6,144.00View SEC Filing  
12/15/2016Richard P SheaCFOSell9,799$15.00$146,985.00View SEC Filing  
12/9/2016Richard P SheaCFOSell1,451$15.00$21,765.00View SEC Filing  
11/22/2016Bruce LeicherSVPSell1,030$13.66$14,069.80View SEC Filing  
11/22/2016Craig A. WheelerPresidentSell5,880$13.68$80,438.40View SEC Filing  
11/22/2016James M RoachVPSell1,091$13.67$14,913.97View SEC Filing  
11/22/2016Richard P SheaCFOSell971$13.67$13,273.57View SEC Filing  
8/22/2016Bruce LeicherSVPSell1,030$12.05$12,411.50View SEC Filing  
8/22/2016Craig A. WheelerPresidentSell5,880$12.02$70,677.60View SEC Filing  
8/22/2016James M RoachVPSell1,091$12.05$13,146.55View SEC Filing  
8/22/2016Richard P SheaCFOSell972$12.05$11,712.60View SEC Filing  
5/20/2016Bruce LeicherSVPSell1,000$10.40$10,400.00View SEC Filing  
5/20/2016Craig A WheelerPresidentSell5,880$10.18$59,858.40View SEC Filing  
5/20/2016Ganesh Venkataraman KaundinyaVPSell1,050$10.18$10,689.00View SEC Filing  
5/20/2016Richard P SheaCFOSell973$10.18$9,905.14View SEC Filing  
5/19/2016John E BishopVPSell784$10.20$7,996.80View SEC Filing  
4/19/2016John E BishopVPSell2,843$9.57$27,207.51View SEC Filing  
2/23/2016John E BishopVPSell329$9.70$3,191.30View SEC Filing  
2/22/2016Bruce LeicherSVPSell227$9.65$2,190.55View SEC Filing  
2/22/2016Craig A WheelerPresidentSell1,688$9.95$16,795.60View SEC Filing  
2/22/2016John E BishopVPSell2,848$9.66$27,511.68View SEC Filing  
2/19/2016Bruce LeicherSVPSell2,000$9.64$19,280.00View SEC Filing  
2/19/2016Craig A WheelerPresidentSell9,844$9.37$92,238.28View SEC Filing  
2/19/2016John E. BishopVPSell357$10.28$3,669.96View SEC Filing  
2/19/2016Richard P SheaCFOSell1,823$9.64$17,573.72View SEC Filing  
2/18/2016Bruce LeicherSVPSell337$10.49$3,535.13View SEC Filing  
2/18/2016James M RoachVPSell272$10.49$2,853.28View SEC Filing  
2/18/2016Richard P SheaCFOSell183$10.49$1,919.67View SEC Filing  
2/17/2016Craig A WheelerPresidentSell1,688$11.30$19,074.40View SEC Filing  
12/11/2015Michael FrankenInsiderSell520$15.84$8,236.80View SEC Filing  
11/20/2015Craig A WheelerPresidentSell1,766$17.86$31,540.76View SEC Filing  
11/19/2015Craig A WheelerPresidentSell2,061$18.05$37,201.05View SEC Filing  
11/17/2015Craig A WheelerPresidentSell1,766$17.70$31,258.20View SEC Filing  
11/5/2015Craig A. WheelerPresidentSell51,667$18.00$930,006.00View SEC Filing  
8/20/2015Craig A WheelerPresidentSell1,766$22.28$39,346.48View SEC Filing  
8/19/2015Craig A WheelerPresidentSell2,061$22.02$45,383.22View SEC Filing  
8/19/2015James M. RoachVPSell7,011$22.09$154,872.99View SEC Filing  
8/18/2015James M RoachVPSell6,812$21.80$148,501.60View SEC Filing  
8/17/2015Craig A WheelerPresidentSell1,766$21.77$38,445.82View SEC Filing  
7/15/2015Elizabeth StonerDirectorSell4,570$22.35$102,139.50View SEC Filing  
6/19/2015John E BishopVPSell21,274$25.50$542,487.00View SEC Filing  
6/18/2015Bruce LeicherSVPSell20,000$23.00$460,000.00View SEC Filing  
6/18/2015Craig A WheelerPresidentSell155,000$24.20$3,751,000.00View SEC Filing  
6/18/2015John E BishopVPSell36,313$23.58$856,260.54View SEC Filing  
6/4/2015Craig A WheelerPresidentSell103,333$22.00$2,273,326.00View SEC Filing  
6/1/2015Bruce LeicherSVPSell40,000$21.00$840,000.00View SEC Filing  
6/1/2015James M RoachVPSell25,000$21.70$542,500.00View SEC Filing  
5/20/2015Craig A WheelerPresidentSell1,766$19.68$34,754.88View SEC Filing  
5/19/2015Craig A WheelerPresidentSell2,061$19.67$40,539.87View SEC Filing  
4/23/2015Craig A WheelerPresidentSell51,667$20.00$1,033,340.00View SEC Filing  
4/23/2015Ganesh Venkataraman KaundinyaVPSell34,000$19.95$678,300.00View SEC Filing  
4/20/2015Craig A WheelerPresidentSell6,269$18.75$117,543.75View SEC Filing  
4/17/2015Bruce LeicherSVPSell52,910$19.52$1,032,803.20View SEC Filing  
4/16/2015James M RoachVPSell50,000$18.70$935,000.00View SEC Filing  
3/16/2015Richard P SheaCFOSell23,093$15.10$348,704.30View SEC Filing  
3/5/2015Richard P SheaCFOSell23,364$14.90$348,123.60View SEC Filing  
2/24/2015Craig A WheelerPresidentSell2,110$13.52$28,527.20View SEC Filing  
2/20/2015Bruce LeicherSVPSell1,891$12.97$24,526.27View SEC Filing  
2/20/2015Craig A WheelerPresidentSell9,563$13.49$129,004.87View SEC Filing  
2/20/2015John E BishopVPSell1,768$12.97$22,930.96View SEC Filing  
2/20/2015Richard P SheaCFOSell1,812$12.97$23,501.64View SEC Filing  
2/18/2015Craig A WheelerPresidentSell1,688$11.91$20,104.08View SEC Filing  
12/15/2014Bennett M ShapiroDirectorSell5,800$12.19$70,702.00View SEC Filing  
12/11/2014Michael FrankenInsiderSell2,047$12.29$25,157.63View SEC Filing  
12/1/2014Bennett M ShapiroDirectorSell9,903$12.00$118,836.00View SEC Filing  
11/28/2014Bennett M ShapiroDirectorSell1,897$12.00$22,764.00View SEC Filing  
11/25/2014Craig A WheelerPresidentSell2,210$11.59$25,613.90View SEC Filing  
11/20/2014Craig A WheelerPresidentSell1,768$11.10$19,624.80View SEC Filing  
11/17/2014Craig A WheelerPresidentSell1,768$10.58$18,705.44View SEC Filing  
10/3/2014Bennett M ShapiroDirectorSell3,723$12.00$44,676.00View SEC Filing  
9/12/2014Peter Barton HuttDirectorSell3,640$11.42$41,568.80View SEC Filing  
8/25/2014Craig A WheelerPresidentSell2,209$11.45$25,293.05View SEC Filing  
8/20/2014Craig A WheelerPresidentSell1,768$11.54$20,402.72View SEC Filing  
8/15/2014Bennett M ShapiroDirectorSell3,722$12.00$44,664.00View SEC Filing  
8/15/2014Craig A WheelerPresidentSell1,768$11.75$20,774.00View SEC Filing  
8/13/2014Bennett M ShapiroDirectorSell3,721$12.00$44,652.00View SEC Filing  
5/23/2014Craig A WheelerPresidentSell2,110$12.06$25,446.60View SEC Filing  
5/20/2014Craig WheelerPresidentSell1,688$12.08$20,391.04View SEC Filing  
5/15/2014Craig WheelerPresidentSell1,687$11.09$18,708.83View SEC Filing  
2/25/2014Craig WheelerPresidentSell2,109$17.47$36,844.23View SEC Filing  
2/24/2014John BishopVPSell1,038$17.67$18,341.46View SEC Filing  
2/19/2014Craig WheelerPresidentSell3,797$17.90$67,966.30View SEC Filing  
2/12/2014Ganesh Venkataraman KaundinyaVPSell33,000$17.96$592,680.00View SEC Filing  
1/9/2014John BishopVPSell27,159$19.50$529,600.50View SEC Filing  
11/25/2013Bruce LeicherSVPSell13,492$18.00$242,856.00View SEC Filing  
11/25/2013Craig WheelerPresidentSell2,215$17.77$39,360.55View SEC Filing  
11/25/2013Ganesh Venkataraman KaundinyaVPSell33,211$18.02$598,462.22View SEC Filing  
11/19/2013Craig WheelerPresidentSell2,215$17.17$38,031.55View SEC Filing  
11/15/2013Craig WheelerPresidentSell1,772$16.88$29,911.36View SEC Filing  
10/11/2013John BishopVPSell5,247$15.46$81,118.62View SEC Filing  
8/23/2013Craig WheelerPresidentSell2,109$14.90$31,424.10View SEC Filing  
8/20/2013Craig WheelerPresidentSell2,109$14.47$30,517.23View SEC Filing  
8/15/2013Craig WheelerPresidentSell1,688$15.43$26,045.84View SEC Filing  
7/26/2013Richard P SheaCFOSell30,000$16.61$498,300.00View SEC Filing  
6/27/2013Richard P SheaCFOSell10,522$14.61$153,726.42View SEC Filing  
6/19/2013Richard P SheaCFOSell21,550$14.61$314,845.50View SEC Filing  
5/23/2013Craig A WheelerPresidentSell2,109$13.03$27,480.27View SEC Filing  
5/21/2013Craig A WheelerPresidentSell2,109$12.83$27,058.47View SEC Filing  
5/15/2013Craig A WheelerPresidentSell1,687$13.33$22,487.71View SEC Filing  
3/5/2013Elizabeth StonerDirectorSell2,040$14.00$28,560.00View SEC Filing  
2/15/2013Bruce LeicherSVPSell1,040$12.26$12,750.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Momenta Pharmaceuticals (NASDAQ:MNTA)
Latest Headlines for Momenta Pharmaceuticals (NASDAQ:MNTA)
Source:
Loading headlines, please wait.

Social

Chart

Momenta Pharmaceuticals (MNTA) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.